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Abstract
Despite high vaccine coverage, pertussis has re-emerged as a public health
concern in many countries. One hypothesis posed for re-emergence is the waning
of immunity. In some disease systems, the process of waning immunity can be
non-linear, involving a complex relationship between the duration of immunity
and subsequent boosting of immunity through asymptomatic re-exposure.
We present and analyse a model of infectious disease transmission to exam-
ine the interplay between infection and immunity. By allowing the duration
of infection-acquired immunity to differ from that of vaccine-acquired immu-
nity, we explore the impact of the difference in durations on long-term disease
patterns and prevalence of infection.
Our model demonstrates that vaccination may induce cyclic behaviour, and
its ability to reduce the infection prevalence increases with both the duration
of infection-acquired immunity and duration of vaccine-acquired immunity. We
find that increasing vaccine coverage, while capable of leading to an increase
in overall transmission, always results in a reduction in prevalence of primary
infections, with epidemic cycles characterised by a longer interepidemic period
and taller peaks.
Our results show that the epidemiological patterns of an infectious disease
may change considerably when the duration of vaccine-acquired immunity dif-
fers from that of infection-acquired immunity. Our study highlights that for any
particular disease and associated vaccine, a detailed understanding of the dura-
tion of protection and how that duration is influenced by infection prevalence
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is important as we seek to optimise vaccination strategies.
Keywords: infectious disease modelling, vaccination, waning immunity,
pertussis
1. Introduction
The complex dynamics of waning immunity, whether the immunity be ac-
quired through natural infection or through vaccination, play a key role in shap-
ing the epidemiological patterns of an infectious disease. Where immunity is
temporary, it wanes over time but may be subsequently boosted upon asymp-
tomatic reexposure, as observed for measles (Whittle et al., 1999) and pertussis
(Cattaneo et al., 1996). Mathematical models of vaccine-preventable infectious
diseases (Glass and Grenfell, 2003; A´guas et al., 2006; Wearing and Rohani,
2009; Lavine et al., 2011; Campbell et al., 2016) are based on the susceptible-
infectious-recovered-susceptible (SIRS) framework (Keeling and Rohani, 2008),
where every individual in a population is categorised by one of three states
based on his or her immune status: susceptible (S) to infection, infected and
infectious (I) if they can transmit the infection, and recovered (R) from infection
and immune. As immunity wanes, recovered individuals become susceptible to
infection again.
Since the advent of vaccination, mathematical models have been invaluable
to vaccination programme design. Key contributions include the introduction of
the concept of the basic reproductive ratio R0 (Diekmann et al., 1990; Heester-
beek, 2002; Heffernan et al., 2005) and herd immunity thresholds (Fine, 1993).
Models provide guidance on optimal vaccination strategies (Hethcote et al.,
2004; Campbell et al., 2015, 2017) and reveal insights into the impact of vac-
cination programmes that may seem counter-intuitive due to nonlinearities in
the transmission process.
Vaccines can induce protection against infection, against severe disease,
against infectiousness, or a combination of these (Siegrist, 2008; Pre´ziosi and
Halloran, 2003a,b). There are multiple ways through which a vaccine may fail
to provide sterilising immunity, such as degree of protection and duration of
protection (McLean and Blower, 1993). They can provide incomplete protec-
tion by, for example, reducing the susceptibility by some degree. Furthermore,
the protection provided may wane over time.
The reemergence of pertussis over the last two decades has motivated studies
on the persistence of immunity to this disease. These studies have found that
infections following pertussis vaccination may occur and that these secondary
infections may be less severe or asymptomatic, which suggest that protection
against infection is shorter than protection against disease (Long et al., 1990;
Cherry, 1996; Srugo et al., 2000; Wendelboe et al., 2005). The duration of
infection-acquired immunity has been estimated to be approximately 60 years
(Wearing and Rohani, 2009), compared to a considerably shorter duration of
vaccine-acquired immunity of 4–12 years (Wendelboe et al., 2005). It remains
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an open challenge to determine the vaccine failure mechanism through which a
vaccinated individual becomes infected.
In our study, we focus on the effects of a vaccine with protection that wanes
over time. We investigate the influence on infection prevalence as the difference
between the durations of vaccine- and infection-acquired immunity is varied.
In Section 2, we develop our extension to the SIRS-type model by introducing
differences between immunity acquired after natural infection and after vaccina-
tion. We analyse the model in Section 3. The results are presented in Section 4,
where we illustrate how infection prevalence changes with vaccine coverage and
duration of immunity. Also, we compare the differences in infection prevalence
under two different mechanisms through which a vaccine may act to provide
protection. A summary of our findings and their relevance are discussed in
Section 5.
2. The SIRWS model with differences in duration of immunity after
natural infection or vaccination
Our model is an extension to the susceptible-infectious-recovered-waning-
susceptible (SIRWS) model studied by Lavine et al. (2011) through the inclusion
of differences between the duration of infection-acquired immunity and vaccine-
acquired immunity. In our extended model, we distinguish between primary and
secondary infections to investigate how disease severity, assumed to be lower for
secondary infections, may potentially impact case notifications.
Individuals are categorised into one of eight states depending on their im-
mune status. The susceptible population is divided into those who are able to
acquire a primary infection (S1) and those who can acquire a secondary infection
(S2). Similarly, the infectious population is divided into those with a primary
(I1) or secondary (I2) infection. The recovered (R) state represents those who
have recovered from and are fully immune to infection. They transition to the
waning (W ) state when their immunity has waned sufficiently. From there, they
can become susceptible to secondary infections (transition to S2), or have their
immunity boosted upon reexposure (return to R).
Vaccination is represented in the model by a fraction of newborns entering
the population through the vaccinated (V ) state, where they are temporarily
fully protected against infection. As vaccine-acquired immunity wanes, vacci-
nated individuals enter the waning vaccine-acquired immunity (Wv) state. Over
time, they either lose all immunity and become susceptible to primary infection
(S1), or their immunity may be boosted. Under our first model for how vacci-
nation provides protection, upon a boosting of vaccine-acquired immunity, the
vaccinated individual enters the R compartment, where subsequent waning of
immunity would lead them to S2. Should they then become infectious, they
would be infected with a secondary infection (with lower disease severity)—
bypassing a primary infection. The model is described by the following system
of differential equations for the proportions of the population in each state:
dS1
dt
= (1− p)µ− λS1 + 2κvWv − µS1 , (1a)
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dI1
dt
= λS1 − γI1 − µI1 , (1b)
dR
dt
= γI1 + γI2 − 2κnR+ νλW + νλWv − µR , (1c)
dW
dt
= 2κnR− 2κnW − νλW − µW , (1d)
dS2
dt
= 2κnW − λS2 − µS2 , (1e)
dI2
dt
= λS2 − γI2 − µI2 , (1f)
dV
dt
= pµ− 2κvV − µV , (1g)
dWv
dt
= 2κvV − 2κvWv − νλWv − µWv . (1h)
The rate at which the proportion of susceptible individuals acquires an infec-
tion and becomes infectious is the force of infection, denoted by λ = β(I1 + I2),
where β is the transmission coefficient. Secondary infections are considered
equally infectious as primary infections, both with an average recovery time of
1/γ. Births and deaths occur at an equal rate µ, so that the population size
is constant, and disease-induced mortality is ignored. The proportion of births
entering the vaccinated state is denoted by p.
The waning of natural immunity is modelled as a two-step process from R
to S2 via the state W . We use the method of stages (Lloyd, 2001) to model this
transition with the parameter κn. In the absence of boosting, the transition
time from R to S2 is 2/(2κn + µ), so that for µ  κn, the average duration of
immunity is approximately 1/κn, the same mean duration as for the standard
SIRS model with immunity waning rate κn. The waning of vaccine-acquired
immunity (from V to S1 at rate κv) is similarly defined. Immune boosting
occurs at a rate νλ, where ν is the strength of immune boosting relative to the
force of infection (ν > 0). Allowing ν > 1 implies that boosting requires lower
exposure than for a transmissible infection. See Table 1 for a description of the
state variables and parameters.
Under our second model for vaccination protection, we consider the case
where the boosting of vaccine-acquired immunity delays (rather than bypasses)
a primary infection. This can be examined by reformulating Equations (1c) and
(1g) into
dR
dt
= γI1 + γI2 − 2κnR+ νλW − µR ,
dV
dt
= pµ+ νλWv − 2κvV − µV .
The flow diagrams for each of these vaccine-acquired immune boosting mecha-
nisms are illustrated in Figure 1.
Our extended SIRWS model in Equation (1) collapses to the SIRWS model
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Figure 1: (Colour online) A diagram of the extended SIRWS model with infection-acquired and
vaccine-acquired immunity. The population is divided into eight different states, represented
by boxes. A boosting of vaccine-acquired immunity may either bypass the primary infection
(blue dash-dotted line) or delay the primary infection (red dashed line). The death rate µ is
denoted by a bullet.
studied by Lavine et al. (2011) under the following substitutions:
S = S1 + S2 ,
I = I1 + I2 ,
R = R+ V ,
W = W +Wv ,
κ = κn = κv .
Dafilis et al. (2012) have shown that the inclusion of immune boosting allows the
SIRWS model to produce limit cycles in the absence of vaccination—dynamics
that are qualitatively different to the standard SIRS model. Further, Leung
et al. (2016) observed that limit cycles were absent in the SIRWS model when
immune boosting occurred at a rate less than the force of infection (that is,
ν < 1). Additionally, for limiting values of waning immunity (κ → 0 and
κ → ∞), the extended model reduces to the standard SIR and SIS model
respectively.
3. Methods
The extended SIRWS model described by Equation (1) was numerically in-
tegrated in MATLAB 2014b’s ode45 ODE solver (The MathWorks Inc., Natick,
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Parameter Description Default
p vaccinated proportion of the population (varies)
β transmission coefficient 260 y−1p−1
γ recovery rate 17 y−1
ν strength of immune boosting relative to the force of infection 3
κn rate of loss of infection-acquired immunity (varies) y−1
κv rate of loss of vaccine-acquired immunity (varies) y−1
µ birth and death rate 1/80 y−1
State Description
S1 susceptible to primary infection
I1 infectious with primary infection
R recovered from an infection and fully immune
W recovered from an infection with waning immunity
S2 susceptible to a secondary infection
I2 infectious with secondary infection
V vaccinated and fully immune
Wv vaccinated with waning vaccine-acquired immunity
Table 1: Descriptions of the parameters and state variables. (y = years; p = person)
Massachusetts) with absolute and relative tolerance both set to 1× 10−8. The
system was run for 1300 years with the first 700 years discarded as transient.
Initial conditions were set to be close to the endemic equilibrium of the SIRWS
model (Lavine et al., 2011) in the absence of vaccination:
(S1, I1, R,W ) = (0.065, 0.001, 0.760, 0.174)
and all other states were set to 0.
The transmission coefficient and recovery rate (β and γ respectively) were
taken from Lavine et al. (2011) in their study of pertussis. Other parameter
values were chosen so that the model produces periodic cycles in the absence
of vaccination. As per Leung et al. (2016), the relative strength of immune
boosting ν was set to 3. The average life expectancy (1/µ) was set to 80 years.
The default model parameters are detailed in Table 1.
As we examine the influence of duration of immunity on the epidemiological
patterns of disease, we introduce Tn = 1/κn and Tv = 1/κv to denote the
average duration of infection- and vaccine-acquired immunity respectively (in
the absence of immune boosting). We allow Tn to range over 5–80 years, which
covers suggested estimates for the duration of immunity following a pertussis
infection. In Lavine et al. (2011)’s study of vaccination using the SIRWS model
it was assumed that Tv and Tn were equal. In our study, we consider the case
where the duration of vaccine-acquired immunity is less than or equal to that
of infection-acquired immunity. Accordingly, the duration of vaccine-acquired
immunity Tv ranges from 2 years to as high as the corresponding Tn.
To generate diagrams of the mean infection prevalence as a function of the
vaccinated proportion (p), duration of vaccine-acquired immunity (Tv), and du-
ration of infection-acquired immunity (Tn), the values of Tv were chosen as
follows. For Tn ≤ 30 years, Tv was chosen by dividing Tn into five equal inter-
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vals. For Tn > 30 years, Tv was set to intervals of 10 years up to the respective
Tn.
The average infection prevalence was calculated as the mean of the time
series of the infectious proportion (I1 + I2) over 40 peaks in the presence of
periodic cycles. Where periodic cycles were absent, the average infection preva-
lence was set to be equal to the numerically obtained endemic equilibrium of
the system. The distribution of the population over the eight different states
was similarly calculated. Bifurcation analyses were performed in XPPAUT 8.0
(Ermentrout, 2002) with an adaptive step size Runge–Kutta integrator.
4. Results
In our extended SIRWS model, we explore two mechanisms of vaccine pro-
tection, where vaccine-acquired immune boosting may either bypass or delay
the primary infection. We find that the qualitative behaviour of the model
under both mechanisms is similar. Hence, we present the results for the mecha-
nism where vaccine-acquired immune boosting bypasses the primary infection.
We provide the corresponding figures for the alternative mechanism in the Ap-
pendix.
4.1. Influence of vaccination to lower infection prevalence is more sensitive to
the duration of infection-acquired immunity than of vaccine-acquired im-
munity.
We first examine the impact of vaccine coverage and waning immunity on the
mean infection prevalence (I1 + I2). Figure 2 shows the mean infection preva-
lence for eight different durations of infection-acquired immunity, Tn, and vary-
ing durations of vaccine-acquired immunity, Tv. For relatively short infection-
acquired immunity Tn = (10, 20, 30), waning immunity is a transient process
relative to the demographic time scale. For long-lived infection-acquired immu-
nity (Tn ≥ 40), the duration of immunity becomes comparable to demographic
time scales. The gray dashed line marks the mean infection prevalence in the
absence of vaccination. As vaccination is introduced (p > 0), the infection
prevalence is characterised by a stable endemic equilibrium (Figure 2b–h). As
p increases, the endemic equilibrium bifurcates via a Hopf bifurcation—denoted
by the black circle—into stable periodic cycles, and the mean infection preva-
lence is calculated from a time series over 40 cycles. For Tn = 10 (Figure 2a),
the Hopf bifurcation occurs at a non-biological region (p < 0) and thus is not
shown.
The ability of a vaccine to reduce infection prevalence increases with the
duration of both infection- and vaccine-acquired immunity. When natural im-
munity is relatively short (Tn ≤ 30), the reduction in infection prevalence is
more sensitive to the duration of infection-acquired immunity (Figure 2a–c). For
long-lived natural immunity (Tn ≥ 40), the duration of vaccine-acquired immu-
nity has a larger influence on reducing the infection prevalence (Figure 2d–h).
The mean infection prevalence generally declines as vaccine coverage increases.
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Figure 2: (Colour online) The mean infection prevalence for varying vaccinated proportion,
duration of infection-acquired immunity (plots) and duration of vaccine-acquired immunity
(colours). The gray dashed line indicates the mean infection prevalence in the absence of
vaccination (p = 0). The black circle on each line denotes the Hopf bifurcation point that
generates periodic cycles.
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However, when natural immunity is relatively short-lived, the mean infection
prevalence may reach a level greater than that without vaccination, as observed
in Figure 2a–b. We examine this surprising result in detail in Section 4.2.
Similar behaviour in infection prevalence is observed when the boosting of
vaccine-acquired immunity delays (rather than bypasses) a primary infection
(see Appendix A), or when the demographic timescale changes (see Appendix
B). In the former case, while the behaviours of our extended SIRWS model
under two different mechanisms of vaccine protection are generally similar, the
vaccinated proportion has a bigger influence on decreasing the mean infection
prevalence in the system where the boosting of vaccine-acquired immunity by-
passes the primary infection. In the latter case, extending the average life
expectancy would allow the process of waning immunity to be more transient
(or alternatively, more comparable if average life expectancy decreases). For
a given duration of natural immunity and a vaccine with a fixed duration of
protection, the ability of a vaccine to further reduce infection decreases as the
average life expectancy increases.
In the context of pertussis, the estimated duration of immunity after a per-
tussis infection ranges from 3.5 years (Versteegh et al., 2002) to lifelong (Gordon
and Hood, 1951) (though improved diagnostic testing over time may be a con-
tributing factor to the striking difference). In turn, the ability of a vaccine to
lower infection prevalence also varies considerably. For example, for a vaccine
lasting an average of say, 10 years, the model shows a greater reduction in in-
fection when the duration of natural immunity is 60 years compared to when it
is 10 years.
4.2. The mean primary infection prevalence decreases as vaccine coverage in-
creases, but the mean total infection prevalence can increase
Here we examine the surprising result from Section 4.1 that the mean total
infection prevalence may reach a level greater than that without vaccination
as vaccine coverage increases. We remind the reader that the total infection
prevalence is the sum of two infectious states, I1 + I2. To look further into the
behaviour of each of these infectious states, we calculated the mean proportion
of each immune status state (the eight compartments of the extended SIRWS
model).
Although the mean total infection prevalence may increase with vaccine cov-
erage, the mean primary infection prevalence always decreases with increasing
duration of vaccine-acquired immunity and vaccine coverage. However, this de-
crease in primary infection may be countered by an increase in transmission
from secondary infections.
Figure 3 shows the distribution of the population for the extended SIRWS
model under both mechanisms of vaccination protection: where the boosting of
vaccine-acquired immunity bypasses (top) or delays (bottom) a primary infec-
tion. Indeed, Figure 3b and d show that the mean primary infection prevalence
is always decreasing as vaccine coverage increases, regardless of whether the
mean was calculated over a stable fixed point or periodic cycles. Figure 3f
shows that an increasing mean secondary infection prevalence may contribute
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Figure 3: (Colour online) The mean of the eight states for the extended SIRWS model in
which a boosting of vaccine-acquired immunity bypasses (top) or delays (bottom) a primary
infection. (Tn = 60 years; Tv = 6 years)
to an increase in mean total infection prevalence, despite a reducing proportion
of primary infections.
In the context of an infectious disease, a primary infection may be asso-
ciated with severe disease, and a secondary infection be considered mild or
asymptomatic. Vaccination could plausibly act by protecting the individual
from disease (if not by blocking the infection altogether). This may potentially
lead to a reduction in morbidity and consequently fewer case notifications.
4.3. The peak in infection prevalence decreases with increasing duration of infection-
acquired immunity
In addition to the mean infection prevalence, the peak height and interepi-
demic period of the periodic cycles are important measures to consider. The
maximum proportion of infectious cases in the presence of periodic cycles is
shown in Figure 4a–b for a low and moderate vaccinated proportion at p = 0.2
(a) and p = 0.6 (b) respectively. The shaded region indicates when vaccine-
acquired immunity lasts longer than infection-acquired immunity, and the dashed
line shows where their durations are the same. For vaccine-preventable child-
hood infectious diseases such as measles or pertussis, the biologically plausible
parameter space is where Tn ≥ Tv (unshaded area).
The peak heights of the periodic cycles are best described by considering the
duration of natural immunity transitioning from long-lived to short-lived. The
long-term dynamics of the SIRWS system as Tn → ∞ are characterised by a
fixed point attractor, similar to the SIR model. As Tn decreases (moving from
right to left in Figure 4a), the peak heights start from being equal to the stable
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Figure 4: (Colour online) The infection prevalence peaks for varying durations of infection-
acquired immunity (Tn) and durations of vaccine-acquired immunity (Tv), illustrated through
contour plots (a–b) and time series (c–d). The shaded area shows where Tv > Tn, and the
gray dashed line shows where Tv = Tn. Between the Hopf bifurcation branches (shown by red
dash-dotted lines) are contour lines of the peak heights of the infectious proportion. The line
with filled circles indicates the points in parameter space with the maximum peak height of
the periodic cycles.
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Figure 5: (Colour online) The interepidemic period of the SIRWS model at p = 0.6 where
the boosting of vaccine-acquired immunity bypasses (a) or delays (b) a primary infection.
The gray dashed line indicates where the duration of infection-acquired and vaccine-acquired
immunity are the same. The red dash-dotted line represents the branch of Hopf bifurcations,
where the period is approximately 1.
fixed point (with an amplitude of 0 in the absence of periodic cycles) until a Hopf
bifurcation (shown by a red dash-dotted line) gives rise to stable periodic cycles.
For lower values of Tn still, the periodic cycles lose stability through a second
Hopf bifurcation, and the dynamics are characterised by a stable fixed point
once again. After the first Hopf bifurcation (around Tn ≈ 23) as Tn decreases,
for a fixed Tv, the peak height of the periodic cycles monotonically grows until it
reaches a maximum (the line of maximum peak heights for a given Tv is shown
by the line with filled circles). After reaching a maximum, the peak height
decreases again. For clarity, the contour lines for these decreasing peak heights
(between the line with filled circles and the Hopf bifurcation line at Tn ≈ 2) have
been omitted. The behaviour of the peak heights for higher vaccine coverage
at p = 0.6 (Figure 4b) is similar. However, over a decreasing Tn, the Hopf
bifurcation giving rise to periodic cycles occurs at a value of Tn that is higher
than 30 (and is thus not shown).
The duration of vaccine-acquired immunity has a small effect on the epidemic
peak height relative to the duration of infection-acquired immunity, as shown
in Figure 4a–b. There is a noticeable decrease in the maximum proportion of
infectious cases as duration of infection-acquired immunity increases. The dif-
ference in peak height is illustrated through the time series for two different
combinations of immunity durations at p = 0.2 (Figure 4c) and p = 0.6 (Fig-
ure 4d). Additionally, a growing interepidemic period with taller peak height
is observed by increasing the vaccinated proportion (compare Figure 4c to Fig-
ure 4d). These epidemiological patterns are also observed when the boosting
of vaccine-acquired immunity delays (rather than bypasses) a primary infection
(See Appendix A). Taken together, increasing vaccine coverage leads to fewer
primary infections (Figure 3b), with periodic cycles characterised by taller peaks
(Figure 4a–b) and a longer interepidemic period (Figure 4c–d).
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The interepidemic period is also more sensitive to the duration of infection-
acquired immunity than the duration of vaccine-acquired immunity. It grows
with increasing Tn and Tv, as illustrated in Figure 5 at p = 0.6, where the
boosting of vaccine-acquired immunity either bypasses (a) or delays (b) a pri-
mary infection. In the presence of periodic cycles for a small vaccinated propor-
tion, the outbreaks are characterised by lower peaks (Figure 4a) with shorter
interepidemic periods. In contrast, the outbreaks are described by taller peaks
and longer interepidemic periods under a higher vaccinated proportion.
In the public health context, the epidemiological patterns of an infectious
disease may change considerably when the duration of vaccine-acquired immu-
nity differs from the duration of infection-acquired immunity. Although the
mean infection prevalence generally decreases with increasing vaccine coverage
(Figure 2), reducing the cumulative public health burden may concentrate the
burden on public health services into short intervals.
5. Discussion
We have shown with our extended SIRWS model that allowing the duration
of infection-acquired immunity to differ from the duration of vaccine-acquired
immunity can have substantial impact on infection prevalence. The duration of
infection-acquired immunity plays a large role in determining the ability of vac-
cination to reduce infection prevalence. While the advent of periodic cycles can
increase the average infection prevalence as vaccine coverage increases, average
primary infection prevalence always falls with increasing vaccination. The in-
fection peaks decrease in height as the duration of infection-acquired immunity
increases.
Our results show that the epidemiological patterns of disease can change
considerably with variation in the duration of infection-acquired and vaccine-
acquired immunity. The presence of vaccination may induce large-amplitude
oscillations. We have demonstrated that by accounting for longer infection-
acquired immunity than vaccine-acquired immunity, the maximum proportion
of the population that is infectious decreases, and the amplitude of the oscil-
lations becomes smaller. The period of the oscillations grows with the dura-
tion of immunity (both vaccine-acquired and infection-acquired) to decrease the
average infection prevalence. By extending the SIRWS model, we find that in-
creasing vaccine coverage decreases the proportion of primary infections, though
this reduction may be countered by an increase in transmission and secondary
infections.
Our results complement those of Heffernan and Keeling (2009), who also
found that the interplay between immunity and vaccination can induce large-
amplitude oscillations. Our finding that decreased primary infection may not
have a substantial impact on the overall infection prevalence due to secondary
infections is consistent with that of A´guas et al. (2006). Others (A´guas et al.,
2006; Campbell et al., 2016) have included immune boosting into their trans-
mission models. However, different from A´guas et al. (2006) who modelled the
boosting of immunity as an infectious process, our interpretation of boosting
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as a non-infectious process allows immune boosting to be more easily triggered
than a transmissible infection (ν > 1). The results from the SIRWS model de-
pend critically on this assumption; without it the model is unable to generate
sustained oscillations (ν < 1) (Leung et al., 2016).
In the situation where primary infections are associated with disease and sec-
ondary infections are mild or asymptomatic, as observed for pertussis (Mertsola
et al., 1983; Long et al., 1990), increasing vaccine coverage reduces the burden
of disease. However, the peaks associated with the oscillations could stretch
public health services over short intervals.
Vaccines may also reduce an individual’s ability to acquire or transmit a
subsequent infection. We have not explored the potential impact of reduced
susceptibility or reduced infectiousness on the epidemiological patterns of dis-
ease. Indeed, a study by Pre´ziosi and Halloran (2003b) found that pertussis
cases from vaccinated individuals were less contagious. How these reductions
may influence the composition of the infectious population and epidemiological
patterns remains an open question. Our study highlights the importance of
obtaining a better understanding of the persistence of immunity. Untangling
the mechanisms responsible for protection against infection, against disease and
against transmission remains a challenge.
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Appendix A. Corresponding figures of the SIRWS model where the
boosting of vaccine-acquired immunity delays a pri-
mary infection
In this appendix, we repeat the numerical calculations for the extended
SIRWS model where the boosting of vaccine-acquired immunity delays a primary
infection. Figure A.6 shows the mean infection prevalence as a function of the
vaccinated proportion for different values of the duration of infection-acquired
immunity. Figure A.7 displays the peaks of the infection prevalence for varying
durations of immunity.
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Figure A.6: (Colour online) The average infection prevalence for varying vaccinated propor-
tion, duration of infection-acquired immunity (plots) and duration of vaccine-acquired im-
munity (colours), where the boosting of vaccine-acquired immunity delays primary infection.
The gray dashed line indicates the mean infection prevalence in the absence of vaccination
(p = 0). The black circles denote the Hopf bifurcation points that generate periodic cycles.
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Figure A.7: (Colour online) The infection prevalence peaks for varying durations of infection-
acquired immunity (Tn) and durations of vaccine-acquired immunity (Tv), where the boosting
of vaccine-acquired immunity delays a primary infection. Contour plots of the peak heights
of the infectious proportion are displayed for p = 0.2 (a) and p = 0.6 (b). The time series are
shown for p = 0.2 (c) and p = 0.6 (d). The shaded area indicates where Tv > Tn, and the gray
dashed line marks where Tv = Tn. The Hopf bifurcation lines are shown by red dash-dotted
lines. The line with filled circles indicates the points in parameter space with the maximum
peak height of the periodic cycles.
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Appendix B. Mean infection prevalence for different average life ex-
pectancy
In this appendix, we repeat the numerical calculations for the system where
the boosting of vaccine-acquired immunity bypasses primary infection (see Equa-
tion (1)), but with a different average life expectancy. The average infection
prevalence is calculated for an average life expectancy of 50 years (Figure B.8)
and 100 years (Figure B.9).
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Figure B.8: (Colour online) The mean infection prevalence for varying vaccinated proportion,
duration of infection-acquired immunity (plots) and duration of vaccine-acquired immunity
(colours). The gray dashed line indicates the mean infection prevalence in the absence of
vaccination (p = 0). The black circle on each line denotes the Hopf bifurcation point that
generates periodic cycles. (1/µ = 50 years)
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Figure B.9: (Colour online) The mean infection prevalence for varying vaccinated proportion,
duration of infection-acquired immunity (plots) and duration of vaccine-acquired immunity
(colours). The gray dashed line indicates the mean infection prevalence in the absence of
vaccination (p = 0). The black circle on each line denotes the Hopf bifurcation point that
generates periodic cycles. (1/µ = 100 years)
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